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During propagation of modified vaccinia virus Ankara (MVA) encoding HIV 89.6 Env, a few viral foci stained very prominently. Virus cloned
from such foci replicated to higher titers than the parent and displayed enhanced genetic stability on passage. Sequence analysis showed a single
nucleotide deletion in the 89.6 env gene of the mutant that caused a frame shift and truncation of 115 amino acids from the cytoplasmic domain.
The truncated Env was more highly expressed on the cell surface, induced higher antibody responses than the full-length Env, reacted with HIV
neutralizing monoclonal antibodies and mediated CD4/co-receptor-dependent fusion. Intramuscular (IM), intradermal (ID) needleless, and
intrarectal (IR) catheter inoculations gave comparable serum IgG responses. However, intraoral (IO) needleless injector route gave the highest IgA
in lung washings and IR gave the highest IgA and IgG responses in fecal extracts. Induction of CTL responses in the spleens of individual mice as
assayed by intracellular cytokine staining was similar with both the full-length and truncated Env constructs. Induction of acute and memory CTL
in the spleens of mice immunized with the truncated Env construct by ID, IO, and IR routes was comparable and higher than by the IM route, but
only the IR route induced CTL in the gut-associated lymphoid tissue. Thus, truncation of Env enhanced genetic stability as well as serum and
mucosal antibody responses, suggesting the desirability of a similar modification in MVA-based candidate HIV vaccines.
Published by Elsevier Inc.Keywords: Truncated HIV Env; Recombinant modified vaccinia virus Ankara; Mucosal immunityIntroduction
Recombinant vaccinia viruses (VACV), derived from the
replication-deficient modified VACV Ankara (MVA) strain
previously used as an attenuated smallpox vaccine (Mayr et al.,
1975; Stickl et al., 1974), express proteins at a high level (Sutter
andMoss, 1992), stimulate humoral and cellular immunity (Sutter
et al., 1994), are safe even in immunodeficient animals (Stittelaar
et al., 2001) and are unlikely to revert to greater virulence because
the host range defect involves multiple gene deletions (Antoine
et al., 1998; Meyer et al., 1991; Wyatt et al., 1998). Non-human
primate studies have shown that recombinant MVA alone
(Barouch et al., 2001; Durbin et al., 1998; Earl et al., 2002;⁎ Corresponding author. 33 North Drive, MSC 3210, National Institutes of
Health, Bethesda, MD 20892-3210, USA. Fax: +1 301 480 1535.
E-mail address: lwyatt@niaid.nih.gov (L.S. Wyatt).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2007.10.033Hirsch et al., 1996; Men et al., 2000; Negri et al., 2001; Nilsson
et al., 2002; Ourmanov et al., 2000; Stittelaar et al., 2000; Zhu
et al., 2000) or following DNA priming (Amara et al., 2002a,
2001) can prevent or reduce disease caused by numerous viruses
including those related to HIV. Several clinical trials to evaluate
recombinant MVA as a vaccine for HIV prevention and treatment
have been initiated (Cebere et al., 2006; Harrer et al., 2005).
Nevertheless, MVAvectors may need to be further optimized and
additional routes of immunization explored to achieve effective
protection in human trials. In particular, natural transmission of
HIV is through a mucosal surface, and targeting immune re-
sponses to the gastrointestinal entry site before viral dissemination
could protect and more effectively clear virus from the major site
of HIV replication in the intestinal mucosa (Belyakov et al.,
2001a; Veazey et al., 1998; Zhang et al., 1999).
We encountered problems when attempting to express cer-
tain integral membrane proteins at high levels by MVAvectors.
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protein under a relatively weak promoter in order to prevent the
selection of non-expressing mutants (Stittelaar et al., 2000).
Similarly, during the course of experiments with an MVA/HIV
recombinant expressing the HIV envelope glycoprotein (Env),
we encountered a genetic instability problem. As described
here, we isolated a spontaneous mutant with enhanced genetic
stability, which had a 115-amino acid truncation of the cyto-
plasmic domain of Env, induced more intense surface staining
of infected cells with HIV antiserum, grew to a higher titer, and
induced enhanced serum and mucosal antibody responses com-
pared to the parent virus.
Results
Isolation and characterization of recombinant MVA expressing
a truncated HIV Env
Full-length HIV Env gp160 is processed into a transmem-
brane subunit gp41 with cytoplasmic and extracellular domains
and a non-covalently linked gp120 subunit that binds the
cellular receptors. The entire env open reading frame of HIV
clade B strain 89.6, modified only by silent mutations thatFig. 1. Comparison of HIV Env of MVA/89.6 and MVA/89.6T. (A) Foci of MVA/89.
against clade B gp120 at 3 days post-infection. (B) Comparison of MVA/89.6 andMV
MVA/89.6T-infected BS-C-1 cells were metabolically labeled with [35S]methionine
made against HIV IIIBgp140 or mouse D61 MAb against gp41. MWM lane contains
amino acid sequence of the C-terminal region of MVA/89.6 and MVA/89.6T gp41.
signals (YXXΦ, is1 and is2, and LL852/853).eliminated poxvirus transcription termination signals, was
inserted into the MVA genome by homologous recombination.
Live immunostaining with clade B anti-gp140 rabbit serum was
used to identify the recombinant virus, MVA/89.6, which was
clonally purified by repeated plaque isolations. During
subsequent passages of MVA/89.6, however, we noted that
some foci did not stain with Env antiserum, whereas others were
larger and stained more intensely than the majority. The dif-
ference in size and intense immunostaining of the latter was
retained after another clonal purification (Fig. 1A), and one such
isolate was called MVA/89.6T. MVA/89.6T was more stable
than MVA/89.6 as no non Env-staining foci were detected after
propagation of the virus into a working stock. These data sug-
gested that 89.6 Env expression was deleterious for MVA
replication and that there was a growth selection for spon-
taneous mutations that relieved this adverse effect.
The expression of HIV Env in metabolically labeled BS-C-1
cells that were infected with MVA/89.6 or MVA/89.6T was
compared. Infected cell lysates were prepared and the recom-
binant proteins were immunoprecipitated, with either polyclonal
rabbit antiserum (R2144) prepared against the gp140 form of
Env or a monoclonal antibody (MAb) directed against gp41
(D61), and analyzed by SDS–PAGE. Using the polyclonal6 and MVA/89.6T-infected CEF cells were immunostained with T8 mouse MAb
A/89.6T Env proteins by SDS–polyacrylamide gel electrophoresis. MVA/89.6 or
and lysates immunoprecipitated with either rabbit R2144 polyclonal antiserum
standard protein markers with masses in kDa indicated on the side. (C) Derived
Bold type indicates location of previously reported plasma membrane retrieval
Table 1
Comparison of genetic stability of HIV Env expression from independently
passaged MVA/89.6 and MVA/89.6T plaques
Virus Passage a Percentage of non-staining foci b
#1 #2 #3 #4 #5
MVA/89.6 0 c b1 b1 b1 NDd ND
1 38 3 9
3 89 55 100
MVA/89.6T 1 b1 b1 b1 b1 b1
3 b1 b1 b1 b1 b1
5 2 3 b1 3 2
7 13 (27) e 9 (16) 7 (23) 10 (18) 15 (30)
a Each plaque was passaged independently in CEF at an MOI of 1.
b Determined by immunostaining fixed plaques at 3 days post-infection with
MAb T8 which binds gp120.
c Stability determined by directly plating out picked plaque, before passage.
d Not done.
e Determined by immunostaining fixed plaques at 3 days post-infection with
MAbs T33 and T40 which bind gp41.
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gp41 were immunoprecipitated from lysates of cells infected
with MVA/89.6 (Fig. 1B). Although the gp120 expressed by
MVA/89.6T co-migrated with that of MVA/89.6, the MVA/
89.6T gp160 and gp41 bands migrated more rapidly and there
was slightly less proteolytic processing (Fig. 1B). The rapid
migration of gp160 and gp41 was confirmed by immunopre-
cipitation with a gp41-specific MAb (Fig. 1B). Thus, these data
indicated that the gp41 of MVA/89.6T was smaller than that of
89.6. Quantitative Western blotting (described in Materials and
methods) confirmed that total expression of Env by both
constructs was almost identical, but that the amount of cleaved
gp120 was greater in MVA/89.6. Cleaved gp120 represented
54% of the total gp120 and gp160 expressed by the MVA/89.6
construct at 24 h, whereas cleaved gp120 represented 40% of the
total gp120 and gp160 by MVA/89.6T.
DNA sequencing indicated that a single nucleotide deletion
had occurred at position 2215 within the open reading frame of
MVA/89.6T, resulting in a frame shift after aspartic acid 738 and
a premature termination six codons downstream (Fig. 1C).
Therefore, the cytoplasmic tail of the gp41 of MVA/89.6T is 115
amino acids shorter (not counting the 6 non-homologous
residues) than that of MVA/89.6 gp41 (Fig. 1C). This spon-
taneous truncation of Env, which occurred in MVA, is reminis-
cent of similar mutations during in vitro passage of SIV and
HIV-2 that enhance infectivity (Chakrabarti et al., 1989; Hirsch
et al., 1989; Johnston et al., 1993; Kodama et al., 1989;
Mulligan et al., 1992; Tsujimoto et al., 1988).
In order to confirm that the large focus phenotype was due to
the truncated env sequence and not to mutations within theMVAFig. 2. Replication of MVA/89.6 and MVA/89.6T in CEF cells. CEF cells were
infected with MVA/89.6 and MVA/89.6T at MOI of 1 pfu/cell and harvested at
designated time. Titers were determined in CEF by immunostaining with T8
mouse MAb reactive with gp120 Env (A) or with anti-VACV rabbit serum (B).genome in these MVA recombinants, we isolated an additional
virus producing large foci from early passage of MVA/89.6.
Comparison of the env sequence in this isolate to MVA/89.6
revealed a single nucleotide deletion within a 4 C run at position
1295 in gp120 of the Env causing a frame shift and truncation of
the Env. Thus, two independent virus isolates that were picked
because of their formation of large foci had Env truncations.
Growth and genetic stability
BS-C-1 cells were infected at a multiplicity of infection (MOI)
of 1 pfu/cell to compare the growth of MVA/89.6 and MVA/
89.6T. When the virus titers were determined by measuring virus
production byT8MAb immunostaining,whichwould detect only
plaques expressing Env, the MVA/89.6T produced slightly more
infectious virus (Fig. 2A). Greater than 99% of the MVA/89.6T
virus produced was expressing Env by T8 staining. Input MVA/
89.6 virus contained about 20% non-staining plaques which
increased to over 40% at the end of the growth cycle. When virus
titers were determined using anti-VACV serum, viral titers were
similar, suggesting that the non-staining MVA recombinants
contribute to the measured MVA titers in these cases (Fig. 2B).
Further genetic stability was assessed by picking plaques
from MVA/89.6 and MVA/89.6T and passaging them indepen-
dently through 7 passages at an MOI of 1 (Table 1). This anal-
ysis confirms that MVA 89.6 is much less stable than MVA/
89.6T. At passage 7 individual plaques of the MVA/89.6T har-
vests were also assessed by immunostaining with T33 and T40
MAbs directed against Env gp41 and found to include viruses
expressing further truncated Env.
Surface Env expression and antibody reactivity
MVA/89.6T had been isolated because of the bright live
immunostaining of infected permissive chick embryo cells.
However, MVA has a host-range defect for most mam-
malian cells. As our plan was to use the recombinant MVA
Fig. 3. Measurement of HIV Env MAb binding to MVA/89.6- and MVA/89.6T-
infected HeLa cells. (A) Binding of mouse MAbs (indicated on x axis) directed
against gp120 and gp41 to surface of unpermeabilized infected cells determined as
mean fluorescence intensity by FACS analysis (y axis). Ratios of mean fluo-
rescence intensities for MVA/89.6 and MVA/89.6T shown below. (B) Binding of
mouse MAbs directed against gp120 and gp41 to permeabilized infected HeLa
cells. Annotated as in panel A. (C) Binding of human neutralizingMAbs to surface
of unpermeabilized infected cells. Annotated as in panel A.
Fig. 4. MVA/89.6T expresses fusion-competent HIV Env. HeLa cells were
infected with recombinant VACV expressing the bacteriophage T7 RNA poly-
merase and one of the following HIV Env-expressing viruses: vSC60 control
expressing Env from CXCR4-tropic HXB2 strain, vCD43 control expressing
Env from CCR5 tropic Ba-L strain and the two MVA/89.6 viruses expressing
dual tropic Env. The infected HeLa cells expressing Env and T7 RNA poly-
merase were mixed with infected HeLa cells expressing β-galactosidase
regulated by a bacteriophage T7 promoter, either CXCR4 or CCR5, and with
or without CD4. Fusion of the twoHeLa populations resulted in the expression of
β-galactosidase indicated at the left.
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sion of infected human HeLa cells by flow cytometry using
mouse MAbs directed against gp120 or gp41 (Fig. 3A). The
mean fluorescence intensities of cells infected with MVA/89.6T
ranged from 2.0- to 2.7-fold higher than those of MVA/89.6-
infected cells. These differences were specific for HIV Env
since the mean fluorescence intensities obtained with polyclonal
VACV serum were similar for cells infected with MVA/89.6 and
MVA/89.6T (not shown). In addition, the numbers of expres-
sing cells as measured with antibodies to VACV were similar
after infection with either recombinant virus (data not shown).
In contrast to the difference in surface expression of Env,
when permeabilized HeLa cells infected with recombinant vi-
ruses expressing truncated or full-length Env were stained with
the mouse MAbs used above, mean fluorescence intensitieswere comparable, suggesting that similar total amounts of Env
were made (Fig. 3B). This implies that truncated Env was
preferentially transported to the surface.
We also compared the binding of broadly neutralizing human
MAbs to ascertain whether the epitopes on the extracellular
domain of Env were adversely affected by truncation of the
cytoplasmic domain. However, there was also greater binding
of the neutralizing MAbs to the truncated Env compared to full
length (Fig. 3C).
Effect of the truncation on Env function
When the HIV Env is cleaved into gp120 and gp41 subunits,
the fusion domain located in gp41 is exposed allowing CD4/co-
receptor dependent fusion of virus-infected cells. The 89.6 Env is
dual tropic and can use either CXCR4 orCCR5 as the co-receptor.
To assess whether the Env truncation adversely affected fusion
activity, HeLa cells infected with MVA/89.6T or MVA/89.6 were
compared in a fusion assay quantified by β-galactosidase
synthesis (Nussbaum et al., 1994). Both the parental MVA/89.6
and the mutant MVA/89.6T induced fusion of cells expressing
CXCR4 or CCR5,whereas recombinant VACVs expressing other
Env genes were specific for CXCR4 or CCR5 (Fig. 4).
Effects of Env truncation and route of inoculation on serum
antibody responses
Groups of BALB/c mice were immunized with 107 pfu of
either MVA/89.6 or MVA/89.6T by the intramuscular (IM)
needle route at 4-week intervals. Serum anti-HIV Env antibody
was detected by ELISA 4 weeks after the first inoculation but
was increased after the second (Fig. 5A, and data not shown).
No further increase was obtained after a third immunization
(data not shown). Sera collected prior to immunization as well
as after immunization with control MVAwere negative (data not
shown). In four independent experiments, including the ones
depicted in Figs. 5A and B, the ELISA titers were 3.8, 3.7, 2.9,
Fig. 6. Mucosal IgG and IgA to HIV Env induced by MVA/89.6 and MVA/89.6T and
with 107 pfu of virus and boosted at 1 and 2 months by IM and compared to ID, IO, an
(A) and fecal extracts (B) from 5 individual mice were processed as in Materials and m
of individual mouse titers; bars represent the standard error of the mean.
Fig. 5. Serum IgG to HIV Env induced by MVA/89.6 and MVA/89.6Tand effect
of different routes of inoculation. (A) Groups of 8–10 mice were inoculated with
107 pfu of virus and boosted at 1 month by IM inoculations. At 2 weeks after the
second immunization, mice were bled and serum IgG response to HIV Env
determined. (B) Comparison of MVA/89.6T IM route of inoculation with ID, IO,
and IR needleless inoculations. Same protocol was used as in A, but only the
response after 2nd immunization is presented. Titers are the averages from
individual mice and bars represent the standard error of the mean.
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MVA/89.6 ( p= .016, .021, .01, and .13, respectively).
Additional experiments were carried out to compare the
IM route of inoculation with MVA/89.6T with intradermal (ID),
intraoral (IO), and intrarectal (IR) needleless inoculations (Fig. 5B).
The IM, ID, and IR routes consistently gave similar IgG titers
whereas IO was more variable (Fig. 5B and data not shown).
Mucosal IgG and IgA elicited by different inoculation routes
The efficacy of an HIV vaccine may depend on the ability to
induce mucosal immunity. We therefore characterized mucosal
antibody responses after immunization by IM, ID, IO, and IR
routes. 89.6 Env-specific IgG and IgA antibody titers were
determined in lung washes, fecal extracts, and rectal washes at
3 weeks after the third immunization. Following IM inoculations,
MVA/89.6T elicited higher antibody titers from each source than
did MVA/89.6 (Fig. 6). We also compared different routes of
inoculation of MVA/89.6T. IM, ID, and IR routes gave high IgG
in lung washes (Fig. 6A), presumably representing systemic anti-
body perfused through lung capillaries, but low or barely de-
tectable IgA. Although the IO route gave the lowest IgG response
(Fig. 6A), it elicited the highest IgA in lung washings. As shown
in Fig. 6B, immunization by the IR route gave the highest IgG and
the highest IgA in the fecal extracts. Antibody titers in the rectal
washes were low and not enhanced by the IR route of im-
munization (data not shown). All washings and extracts from
mice immunized with control MVA were negative for Env anti-
body (data not shown). Thus, our data demonstrated that MVA/
89.6T induces a higher titer of mucosal antibody compared to
MVA/89.6. In addition mucosal HIV 89.6-specific antibody re-
sponses depend on routes of MVA/89.6T administration.effect of different routes of inoculations. Groups of 8–10 mice were inoculated
d IR needleless inoculations. At 3 weeks after the third inoculation, lung washes
ethods and assayed for mucosal IgG and IgA by ELISA. Results are the averages
Fig. 7. Env-specific CTL responses of spleen cells. Mice received two immunizations 1 month apart with 107 pfu of MVA/89.6 or MVA/89.6T by the IM route. At 2
weeks after 1st and 2nd immunization, splenocytes from individual mice were assayed directly ex vivo with Env or VACV peptide-pulsed P815 cells and cytokine-
expressing cells were quantitated by flow cytometry (A) or stimulated in vitro with Env peptide and assayed in 51Cr release assay (2 weeks after 2nd immunization
only) (B). Open symbols in B represent the % lysis of unpulsed P815 cells by Env stimulated splenocytes.
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T lymphocyte (CTL) responses
To compare the CTL responses elicited by the different
forms of Env, we immunized BALB/c mice with 2 immuniza-
tions of 107 pfu of MVA/89.6 or MVA/89.6T 1 month apart byIM route. Two weeks after the first and second immunization,
mice were sacrificed and splenocytes from individual mice were
assayed directly with Env or vaccinia peptide-pulsed P815 cells.
CD8+ IFN-γ+, CD8+ IFN-γ+ TNF+, and CD8+ IFN-γ+ IL-2+
cells were enumerated by flow cytometry. In addition the same
splenocytes were stimulated in vitro with the Env peptide and
Fig. 9. Detection of long-termmemory CTLs as quantitated by P18-89.6A9/H-2Dd
tetramer staining 13months afterMVA/89.6T immunization.Micewere immunized
three times with 107 pfu of MVA/89.6T by IM, ID, IO, or IR routes. After in vitro
stimulation of spleen cells (pooled splenocytes from 5 mice/group) with P18-
89.6R10 HIV env peptide, cells were double-stained with P18-89.6A9/H-2Dd
tetramer plus anti-CD8 antibody and the number of double positive cells in each
group compared. CON are spleen cells from unimmunized mice.
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induced similar CD8+IFN-γ+, CD8+ IFN-γ+ TNF+, and CD8+
IFN-γ+ IL-2+ cells by ICS staining (Fig. 7A) and similar
specific lytic activities as measured by chromium release
(Fig. 7B). This is consistent with the similar amount of Env
expressed by each construct.
Additional studies were carried out to determine the optimal
routes for inducing effector CTL in mucosal (Peyer's patches)
and systemic (spleen) lymphoid tissues by MVA/89.6T. BALB/
c mice were immunized IM, ID, IO, or IR with 107 pfu of MVA/
89.6T and boosted twice at 4-week intervals. The CTL re-
sponses were measured at 3 weeks after the last immunization.
The splenic CTL responses induced by MVA/89.6Twere higher
by ID, IO, and IR administration than by the IM route (Fig. 8A).
A significant CD8+ CTL lytic activity in the Peyer's patches,
however, was elicited only after IR immunization (Fig. 8A).
Negligible HIV-specific lytic activity was measured using un-
stimulated spleen cells (without peptide) from immunized mice
(data not shown).
Mucosal CD8+ CTL immune responses after immunization
with MVA/89.6T are long lasting
Thirteen months after the last immunization of mice with
MVA/89.6T, we determined the long-term memory P18-
89.6A9-specific CD8+ CTL responses in spleen and in Peyer's
patches. Spleen cells from immunized mice were activated with
P18-89.6A9 peptide for 7 days. The data recapitulated the
functional activity of precursors of CD8+ CTL in vivo. Thus,
the specific lytic responses were higher using spleen cells fromFig. 8. Detection of HIV Env-specific CTL response in spleen cells or Peyer's patches
were immunized three times with 107 pfu of MVA/89.6T by IM, ID, IO, or IR routes.
and pooled splenocytes from 5 mice were stimulated in vitro with P18-89.6R10 HIVmice immunized with MVA/89.6T by IR or ID routes than by
the IM route (Fig. 8B). In addition, long-term memory CTL
were detected in Peyer's patches of mice immunized with MVA/
89.6T by the IR route (Fig. 8B).
To quantify the memory CD8+ CTL elicited by the different
routes of immunizations with MVA/89.6T, a P18-89.6A9/H-
2Dd tetramer that can bind to the T-cell receptor of antigen-
specific CTL was used. After 3 or 7 days of in vitro stimulation
of spleen cells with the P18-89.6A9 peptide, we double-stained
cells with P18-89.6A9/H-2Dd tetramer plus anti-CD8 antibody
and compared the number of double positive cells in each group.
The number of tetramer-positive cells after 7 days stimulation
with peptide was increased dramatically compared to 3 days ofin acutely (A) or long-term (B) infected mice immunized with MVA/89.6T. Mice
Mice were sacrificed at 3 weeks (A) or 13 months (B) after the last immunization
Env peptide.
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CD8+ CTL after IR or ID immunizations was slightly higher
than after IO or IM immunizations (Fig. 9). The high intensity
tetramer-positive cells from mice immunized by IR or ID routes
correlated with the high memory CTL response at 13 months in
the functional 51Cr release assay (Fig. 8B).
Discussion
The purpose of this study was to characterize MVA/89.6T, a
spontaneous mutant derived from recombinant MVA/89.6
expressing a full-length HIV Env, and to compare the immu-
nogenicities of the two viruses. Although MVA/89.6 had been
successfully used to elicit CD8+ CTL responses in mice
(Belyakov et al., 1999, 1998c), the recombinant virus was
troublesome because viral foci that did not stain with HIV
antiserum were noted after serial passages. The gradual ac-
cumulation of non-expressing mutants had been detected with
other recombinant MVAs, suggesting that they can have a
selective growth advantage when the expressed protein exhibits
some toxicity. Serendipitously, however, we observed foci that
were larger and stained more brightly with HIV antiserum than
the majority. Moreover, the mutant was more genetically stable
as non-staining foci were not observed. Biochemical character-
ization revealed a frame shift mutation after amino acid 738 in
the cytoplasmic tail of Env. The more intense staining of the
MVA/89.6T foci, compared to those of MVA/89.6, was con-
sistent with greater surface expression of Env even in non-
permissive cells as determined by flow cytometry. Another in-
dependent truncation mutant was isolated. However, the frame
shift mutation was in gp120, making it undesirable for vaccine
purposes.
The cytoplasmic tails of primate lentivirus Env proteins are
about 150 amino acids, considerably longer than the 20 to 40
amino acids for most other retroviruses (Hunter and Swanstrom,
1990). The role of this domain is not understood and naturally
occurring Env truncations have been observed for SIVand HIV-
2 (Chakrabarti et al., 1989; Hirsch et al., 1989; Johnston et al.,
1993; Kodama et al., 1989; Mulligan et al., 1992; Tsujimoto
et al., 1988), apparently providing a selective advantage under
certain conditions of in vitro propagation. When expressed by
recombinant methods, these truncated Env proteins as well as
those of HIV can provide higher surface expression, greater
syncytium formation, and better exposure of conserved regions
of the ectodomain than the full-length forms (Ashorn et al.,
1990; Earl et al., 1991; Edwards et al., 2002; Haffar et al., 1990;
Mulligan et al., 1992; Ritter et al., 1993; Rowell et al., 1995;
Spies and Compans, 1994; Wyss et al., 2005). Consistent with
the latter findings, the truncated Env described here exhibited
increased surface expression, fusion competence, and reactivity
with a panel of MAbs. Previous studies identified conserved
sequences within the cytoplasmic domain of gp41 that act as
retrieval signals, inducing endocytosis (Berlioz-Torrent et al.,
1999; Bultmann et al., 2001; Byland et al., 2007; Rowell et al.,
1995). These include a membrane proximal tyrosine-based
motif and three distal motifs containing a hydrophobic sequence
in one, dileucine motif in one, and a C-terminal dileucine motif.Our finding of increased surface expression of the spontane-
ously truncated Env emphasizes the importance of the distal
retrieval signals since the tyrosine motif was still present.
Although the HIV Env cytoplasmic domain has been reported to
influence the incorporation of Env into virions, we found that
the truncated Env was associated with virus-like particles when
SIV gag–pol was co-expressed (Earl et al., 2002).
Comparisons of immune responses between mice that re-
ceived DNA vaccines encoding truncated or full-length SIV or
HIV Env demonstrated higher levels of specific antibody
elicited by the truncated forms, which was attributed to greater
expression (Liu et al., 1996; Vzorov et al., 1999). In our study,
we found that the antibody response to HIV-1 89.6 Env induced
by MVA/89.6T in mice by IM route was greater than that
achieved with MVA/89.6 and that MVA/89.6T could induce
similar levels of antibody using several different routes of
inoculation. The higher antibody response could be explained
by the increased surface expression of the truncated Env com-
pared to the full-length protein. However, other factors resulting
from the lower toxicity of the truncated Env in MVA-infected
cells may also have contributed to the beneficial effect. MVA/
89.6 and MVA/89.6T induced similar systemic Env-specific
CTL responses as assayed by ICS and by lytic assays. This is
not surprising since both MVA/89.6 and MVA/89.6T express
similar amounts of Env as determined by quantitative Western
and FACS analysis.
We previously showed that MVA/89.6 induced both
systemic and mucosal CTL responses to Env when adminis-
tered IR to mice (Belyakov et al., 1998c). Moreover, the IR
route overcame prior immunity to VACV that had been admin-
istered systemically (Belyakov et al., 1999). Because HIV
infections commonly involve the mucosal route of entry, we
compared the antibody responses as well as CTL induced by the
MVA/89.6T recombinant given IO, IR, ID, and IM. We found
that the IO and IR routes of inoculation stimulated production of
more IgA in the lung washes and rectal fecal extracts, re-
spectively, than occurred by ID or IM routes. In contrast, the
serum IgG responses were similar by IM, ID, and IR but more
variable by the IO route. The splenic CTL responses induced by
MVA/89.6T were higher when inoculated by ID, IO, and IR
routes than by the IM route. Previously we demonstrated that
long-lasting protection against mucosal viral transmission could
be accomplished by CD8+ CTLs, which must be present in the
mucosal site of exposure (Belyakov et al., 1998a). A significant
P18-89.6A9-specific CD8+ CTL lysis in the Peyer's patches,
however, was elicited only after IR immunization with MVA/
89.6T. Moreover, the memory responses were long lasting as
they were detected at 13 months (last experimental time point)
after the last vaccination in mice.
While correlates of immunity in HIV infection are still not
delineated, both neutralizing antibodies and CTL likely play
important roles in suppressing HIV infection (McMichael,
2006). Our data showing binding of conformational and neu-
tralizing MAbs to the truncated Env suggested that the removal
of a portion of the cytoplasmic domain did not have an adverse
affect on the antigenicity of the extracellular domain. However,
the HIV neutralizing antibody titers in the mice were not high
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(D. Montefiori, personal communication). Based on the studies
described here, we constructed recombinant MVA containing
the truncated HIV 89.6 Env as well as the SIV gag–pol for
vaccine studies in monkeys. Strain-specific neutralizing anti-
body was detected after three or four immunizations (Earl et al.,
2002). Furthermore, ID and IM immunizations with the
recombinant MVA alone or preceded by a DNA vaccine
protected against an IR challenge with the pathogenic SHIV
89.6P (Amara et al., 2001, 2002b; Earl et al., 2002). Moreover,
poorer protection was obtained when the MVA contained only
the gag–pol component of the SHIV vaccine (Amara et al.,
2002a). These data have encouraged us to construct additional
stable recombinant MVA vaccines (L. Wyatt and P. Earl,
unpublished) with truncated HIV Env that have and will soon
enter clinical trials.
Materials and methods
Cell cultures and viruses
The protocols used for generation of recombinant viruses and
their identification by immunostaining have been described in
detail and were carried out in secondary chicken embryo fibro-
blasts (Earl et al., 1998). BS-C-1 cells (ATCC CCl-26) were
grown in modified Eagle's minimal essential medium (EMEM)
supplemented with 10% heat inactivated fetal bovine serum
(FBS) (Hyclone, Logan, UT), 2 mM L-glutamine (Invitrogen,
Carlsbad, CA), 100 U/ml penicillin, and 100 μg/ml streptomycin
sulfate (Invitrogen). Suspension cultures of HeLa S3 cells
(ATCC-CCL-2.2) were grown in MEM for spinner cells (Quality
Biologicals, Inc., Gaithersburg, MD) containing 5% heat-
inactivated equine serum (Hyclone).
Construction of recombinant MVA expressing the full-length
Env of HIV strain 89.6 (referred to asMVA/89.6) was previously
described (Belyakov et al., 1998c). Briefly, the 89.6 env reading
frame was modified by making silent mutations within potential
poxvirus transcriptional termination sequences (Earl et al.,
1990), inserted into deletion II of MVA, and regulated by the
VACV modified early/late H5 promoter (Wyatt et al., 1999).
Unless otherwise mentioned, MVA/89.6T and MVA/89.6 stocks
used for comparative purposes contained N99% and N90% Env-
expressing virus, respectively.
Antibodies
Hybridomas that secrete T8, T43, and D19 MAbs against
linear epitopes in gp120 were derived from mice that had been
immunized with clade B HIV isolate BH8 oligomeric Env
protein (Earl et al., 1994). Similarly derived D61, T32, and T30
MAbs recognize linear epitopes in gp41 while D43, T33, and
T40 are directed against conformational epitopes in gp41 (Earl
et al., 1997). Polyclonal antibody R2144 was made in a rabbit
immunized with gel purified gp140 IIIB Env (P. Earl,
unpublished). Anti-VACV polyclonal antiserum was made in
rabbits. Human neutralizing MAbs derived from HIV infected
individuals directed against gp120 are: 2G12 (Trkola et al.,1996), b12 (Burton et al., 1994), and 447-52D (Gorny et al.,
1992), while 2F5 (Purtscher et al., 1994) is directed against
gp41.
Expression of HIV Env
Radioimmunoprecipitation of virus-infected cell lysates has
been described in detail previously (Wyatt et al., 1996). Briefly,
virus-infected BS-C-1 cells were labeled with 100 μCi/ml of
[35S]methionine (New England Nuclear, Boston, MA) in
methionine-free EMEM containing 5% dialyzed FBS overnight
and then lysed. The cell lysates were incubated overnight with
either antibody R2144 or D61 followed by 20% protein A–
Sepharose suspension. Immunoprecipitated proteins were
resolved by electrophoresis in a 10% SDS–polyacrylamide
gel and visualized by autoradiography.
For quantitative Western blotting, BS-C-1 cells were infected
with MVA/89.6 and MVA/89.6T at a multiplicity of 10 and
harvested at 24 h. Two-fold dilutions of lysates were subjected to
SDS–polyacrylamide gel electrophoresis (PAGE), transferred to
a nitrocellulose membrane, and incubated with mouse T8 MAb
and secondary R-Dye-800CW conjugated donkey anti-mouse
IgG (H+L) (Rockland Immunochemicals, Inc., Gilbertsville,
PA). Reactive bands were quantitated using the Odyssey infrared
imaging system (LI-COR Biosciences, Lincoln, Nebraska).
Band intensities from four consecutive lysate dilutions were
subjected to linear regression analysis using Prism software
(Graph Pad, San Diego, CA) and the slope determined.
Genetic stability of the HIV env genes inMVA/89.6 andMVA/
89.6T was assessed by repeated passages in CEF. Virus was
passaged at anMOI of approximately 1 pfu/cell in CEF, grown for
3 days, harvested, and reinoculated at similar MOI onto freshly
made CEF for each passage. Yields of passaged viruses were
titrated in CEF, using medium containing 0.5% methylcellulose.
After 3 days of incubation, the infected cells were fixed and
stained with MAbs reactive to Env (Earl et al., 1998).
Flow cytometry
Surface and total expression of HIV Env by recombinant
MVA/HIV viruses was quantitated by fluorescent activated cell
sorting (FACS). HeLa S3 spinner cells were infected with MVA
or recombinant MVA at a multiplicity of 5 and incubated at
37 °C in 5% CO2. At 15–18 h post-infection, the cells were
washed with phosphate buffered saline (PBS) containing 3%
FBS (PBS-FBS) and 5×105 cells were dispensed into each well
of a 96 well plate (Corning #3799). Cells were incubated for 1
h at 4 °C with a gp120 or gp41 antibody (as described in
Results) diluted in PBS-FBS and followed by PE conjugated
goat anti-mouse antibody (BD BioSciences, San Jose, CA) or
FITC conjugated anti-human IgG (BD BioSciences) for 30 min
at 4 °C. Following two PBS-FBS washes, the cells were re-
suspended in 2% paraformaldehyde in PBS. For permeabilized
cell studies, 0.1% saponin was added to PBS-FBS at all steps.
Utilizing a FACSCalibur with CellQuest software, 10,000 cells
were acquired and analyzed using FlowJo software (Tree Star,
Inc., Ashland, OR). In each experiment anti-VACV rabbit IgG
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BioSciences) was used as a control to assure that cells were
equally infected.
HIV-1 Env-mediated cell fusion assay
Env-mediated fusion was quantified as previously described
(Nussbaum et al., 1994) with modifications. Effector HeLa cells
were infected with MVA/89.6 or MVA/89.6T and vTF7.3,
expressing bacteriophage T7 RNA polymerase at a multiplicity
of 10. Similarly, target HeLa cells were infected with vCB3
expressing membrane-associated CD4, vCB21R expressing β-
galactosidase and one of two co-receptors (vCBYFI expressing
CXCR4 or vCCR5 expressing CCR5). Following incubation at
31 °C overnight and washing, cells were adjusted to 1×106
cells/ml and 100 μl of infected effector and target cells were
mixed together in duplicate wells. After incubation of plates for
3 h at 37 °C, fusion was quantified by measurement of β-
galactosidase activity using substrate CPRG (Roche Diagnostic,
Indianapolis, IN) in NP-40 treated cell lysates with a
spectrophotometer. Cell fusion activity was expressed as units
of β-galactosidase/min.
Mouse immunizations
Groups of 6–10 BALB/c female mice (approximately
6–10 weeks old) were inoculated with 1×107 pfu of MVA or
recombinant MVA by the following routes: IM, 0.1ml by needle;
ID, 0.1ml by a Biojector 2000 needleless injector (Bioject
Medical Technologies, Inc., Portland, OR); IO, 50 μl by a Syrijet
Mark II needleless injector (Mizzy, Inc., Cherry Hill, NJ) into
buccal mucosa; and IR, 150 μl through an umbilical vein catheter
inserted about 4 cm (Belyakov et al., 1998a). For ID and IO
inoculations, mice were anesthetized with Avertin (stock solution
of 10 g of 2,2,2 tribromethanol in 10 ml of tertiary amyl alcohol).
Avertin was diluted 1:80 and used at a dose of 0.6 ml/25g mouse.
For ID inoculations using Biojector, the mice were shaved and
given 2 injections, one on either side of the base of the tail, lateral
to the spine. For IO injections, the Syrijet was aimed at the buccal
mucosa. For IR inoculations, the inhalation anesthesia methoxy-
flurane (Pitman-Moore, Inc.,Mundelein, IL) was used.Micewere
immunized on day 0 and boosted at 1 month and 2 months. Mice
were bled on day-2, and again 2 weeks after each booster
inoculation.
Mouse mucosal washes collections
Samples of lung lavage, rectal washes, and fecal extracts
were taken from individual mice for antigen-specific IgG and
IgA antibody assays 3 weeks after final immunizations. First,
lung lavage samples were taken under methoxyflurane in-
halation anesthesia. The lungs were flushed with 1 ml of PBS;
this procedure was repeated two times. The lung lavage fluid
collected was then centrifuged at 1200 rpm for 5 min at 4 °C to
remove any cellular debris. After collecting lung lavage samples
mice were sacrificed. Feces were collected into a microcen-
trifuge tube from the intestine and extracted in ratio of 100 mgfeces/1ml PBS; the mixture was vortexed vigorously until the
solution was homogenous. Fecal samples were then spun in a
microcentrifuge at 5000×g for 15 min, and supernatant fluid
from centrifuged fecal homogenates was used for ELISA. For
rectal washes, 1 ml of PBS was gently run though intestinal
tissue from rectum to cecum. The rectal lavage fluid collected
was then centrifuged at 1200 rpm for 15 min to remove any
tissue or fecal matter, and supernatants were collected. All
samples were stored for a short time at −20 °C until assayed and
individually assayed by ELISA.
ELISAs
To measure the levels of IgG and IgA in the sera of mice and
mucosal IgG and IgA in lung and rectal washings and fecal
pellets, 96 well U-bottom plates (Immulon-2; Dynex Technol-
ogies, Chantilly, VA) were coated overnight with sheep anti-
body to the C-terminus of gp120 (International Enzymes, Inc,
Fallbrook, CA) at 0.5 μg/ml in bicarbonate buffer (Roche
Molecular Biochemicals, Indianapolis, IN) followed by purified
89.6 gp140 as described (Earl et al., 2002). Two-fold serial
dilutions of sera or sample suspensions were incubated for 2 h at
room temperature followed by horseradish peroxidase-conju-
gated anti-mouse IgG (Roche Molecular Biochemicals) or
horseradish peroxidase-conjugated anti mouse IgA (Southern
Biotechnology Associates, Inc., Birmingham, AL). BM Blue
substrate (Roche Molecular Biochemicals) was added for
30 min and absorbency read at 370 and 492 nm.
Intracellular cytokine staining
Intracellular cytokine stainingwas performed 2weeks after the
first and second immunization using splenocytes prepared from
individual animals. 2×106 splenocytes were mixed with 1×105
P815 cells that had been pulsed with either the Env V3 peptide
IGPGRAFYTT or the VACV E3L peptide VGPSNSPTF. After
2 h at 37 °C, brefeldin A (Sigma, St. Louis, MO) was added to a
concentration of 10 μg/ml. Four hours later, cells were placed
at 4 °C overnight. Cells were incubated with anti-CD16/32,
clone 2.4G2 (gift of K. Grebe), then stained with peridinin
chlorophyll-a protein (PerCP) conjugated anti-CD8 (clone 53-
6.7, BD Pharmingen). After fixation and permeabilization, cells
were stained with allophycocyanin (APC) conjugated anti-
interferon gamma (IFN-γ) (cloneXMG1.2) and either fluorescein
isothiocyanate conjugated anti-interleukin 2 (IL2) (clone JES6-
5H4) or anti-tumor necrosis factor (TNF) (cloneMP6-XT22) (BD
Pharmingen), washed, and resuspended in 2% paraformaldehyde.
About 100,000 cells were acquired on a FACSCalibur (San Jose,
CA) using Cell Quest and analyzed with FlowJo software (Tree
Star, Inc, Ashland, OR) to determine the percentage of CD8+
splenocytes that expressed IFN-γ, IL2, and TNF.
Cytotoxic T lymphocyte assay
For the data in Fig. 7, spleens from individual mice were
disrupted by Dounce homogenization and subsequent passage
through sterile screens. Erythrocytes were lysed with ACK lysis
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For the data in Fig. 8, spleens from groups of 5 mice were
aseptically removed and pooled and single-cell suspensions
prepared by gently teasing them through sterile screens. The
erythrocytes were lysed in Tris-buffered ammonium chloride
and the remaining cells washed extensively in RPMI 1640
containing 2% fetal bovine serum.
Peyer's patches were carefully excised from the wall of the
small intestine, pooled, and dissociated into single-cell suspen-
sions by enzymatic digestion with collagenase type VIII (300 U/
ml; Sigma, St Louis, MO) and DNAse I (3 U/ml; Sigma) for
60 min. Cells were collected, washed, resuspended in complete
medium (CM; RPMI-1640 supplemented with 10% FBS, 10 U
penicillin (Invitrogen, Carlsbad, CA), 100 μg/ml streptomycin
(Invitrogen), 2 mM glutamine (Invitrogen), 50 μM β-mercap-
toethanol (Invitrogen), and 20 mM Hepes (BioWhittaker)),
layered onto a discontinuous density gradient containing 75%
and 40% Percoll (Pharmacia Inc., Uppsala, Sweden), and
centrifuged at 600×g for 25 min. The interface band containing
cells between the 75% and 40% Percoll was carefully removed
and washed with RP-2. The resulting population was N90%
viable lymphocytes with a cell yield of 1×107 lymphocytes/
mouse. Most Peyers's patches CD3+ T cells isolated from
normal mice were CD4+, while CD3+CD8+ T cells were less
frequent. Collagenase VIII digestion does not alter the ex-
pression of CD3, CD4, or CD8 on splenic Tcells treated with this
enzyme (Belyakov et al., 1998b).
Immune cells from the spleen or Peyer's patches (5×106 perml)
in 12-well culture plates were incubated with 1 μM synthetic
CTL epitope peptide (Env IGPGRAFYTT for data in Fig. 7) or
P18-89.6R10 (IGPGRAFYAR) or P18-89.6A9 (IGPGRAFYA)
(for data in Fig. 8), the minimal epitope of P18-89.6 (Belyakov
et al., 1998c), in complete T cell medium (CTM): RPMI 1640
containing 10% fetal bovine serum, 2 mM L-glutamine, peni-
cillin (100 U/ml), streptomycin (100 mg/ml), and 5×10−5 M 2-
mercaptoethanol. On day 3, we added 10% concanavalin A
supernatant-containing medium (“T-stim”, Collaborative Bio-
medical Products, Bedford, MA) as a source of IL-2. Cytolytic
activity of CTL lines was measured by a 4-h assay with 51Cr
labeled P815 targets tested in the presence or absence of Env
peptide (1μM). For testing the peptide specificity of CTL, 51Cr-
labeled P815 targets were pulsed for 2 h with peptide at the
beginning of the assay. The percent specific 51Cr release was
calculated as 100× (experimental release− spontaneous re-
lease) / (maximum release− spontaneous release). Maximum
release was determined from supernatants of cells that were
lysed by addition of 5% Triton-X 100. Spontaneous release was
determined from target cells incubated without added effector
cells (Belyakov et al., 2000, 2001b). Because our target cells
(P815) express only MHC class I, not class II, we expected that
lysis was mediated by CD8+ class MHC-restricted T cells.
Fluorescent MHC/peptide/avidin tetramer staining of CD8+
CTL phycoerythrin-conjugated H-2Dd tetramers was prepared
as previously described (Belyakov et al., 2000; Dzutsev et al.,
2007), either folded around P18-89.6A9 peptide or around a
“motif” peptide (AGPARAAAL) that bound tightly to the MHC
molecule but did not interact with T cell receptor specific for theH-2Dd/P18-89.6A9 peptide complex. Phycoerythrin-conjugat-
ed H-2Ld tetramers presenting an analogous “motif” peptide
were prepared similarly. T cells were washed in FACS buffer,
blocked for 20 min on ice with Fc block (anti-CD16/CD32), and
then stained with either anti-CD8 (Pharmingen, San Diego,
CA), or 1 ml tetramer PE for 60 min in FACS buffer on ice.
After washing with cold FACS buffer, the cells were analyzed
by flow cytometry.
Statistical analysis
Statistical differences between responses elicited by full-
length and truncated recombinant immunizations of mice were
assessed by Mann–Whitney using Prism software (Graph Pad,
San Diego, CA).
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